Silver Book Fact

Cost-effectiveness of TAVR in sSAS patients

Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY gained and $43,114 per life-year (LY) gained.

Reynolds M, Lei Y, Wang K, et al. Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement. JACC. 2016; 67(1): 29-38. http://www.onlinejacc.org/content/67/1/29

Reference

Title
Cost-Effectiveness of Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement
Publication
JACC
Publication Date
2016
Authors
Reynolds M, Lei Y, Wang K, et al
Volume & Issue
Volume 67, Issue 1
Pages
29-38
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Satisfaction with HVD Treatment
    Among treated heart valve disease (HVD), 96% express “full satisfaction” and 78% are “very satisfied” with their treatment.  
  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
  • From approval in 2011 through 2015 >54,000 TAVRs were performed in 418 centers in 48 states
     
  • Survival Rates of SAS Patients with and without SAVR
    Patients with severe aortic stenosis (SAS) ages 80+ who underwent surgical aortic valve replacement (SAVR) have 1-year, 2-year, and 5-year survival rates of 87%, 78%, and 68% respectively — compared with…  
  • Survival rates of SAS patients ages 80+ with and without SAVR